CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

Core Viewpoint - CASI Pharmaceuticals has received an extension from the Nasdaq Hearings Panel to continue its listing, contingent upon regaining compliance with the Market Value of Listed Securities Rule by February 17, 2026 [1] Company Developments - The Panel's decision was influenced by recent strategic appointments, including a new Chief Executive Officer and a Non-Executive Chairman [1] - The company is focusing on the development of CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [1] - CASI is executing a convertible note purchase agreement and is pursuing additional financing initiatives [1] - There are plans for the divestiture of assets in China as part of the company's strategic realignment [1]